Anti-Infectives · LP-043
Tetracycline Eye ointment
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-043Anti-Infectives
- Generic identity
- TetracyclineEye ointment
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-043
- Generic identity
- Tetracycline
- Presentation
- Eye ointment
- Catalogue strength
- 1%
- Catalogue pack
- Tube 5 g
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Tetracycline.
- Dosage form: eye ointment.
- Catalogue strength / concentration: 1%.
- Catalogue pack: Tube 5 g.
- Catalogue category: Anti-Infectives.
Layer 02 · Unresolved product-specific fields
- Exact active chemical form/basis; the catalogue says tetracycline while external references may describe tetracycline hydrochloride.
- Sterile ophthalmic formulation, ointment base, preservative status and microbial/particulate controls.
- Tube/container-closure specification, applicator instructions and in-use/after-opening period.
- Approved indication/age eligibility, storage, shelf life, registration, manufacturing route and supply status.
Identity note
WHO references confirm that 1% tetracycline ophthalmic ointment exists in public-health use, but they do not establish the active salt, formula, indication or quality status of LP-043.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 1% | Eye ointment | — | Tube 5 g | Do not import tetracycline-hydrochloride identity, trachoma indication, neonatal use or storage conditions from an external comparator. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Tetracycline is an antibiotic that can be formulated as an ophthalmic ointment for specific ocular bacterial infections. An eye ointment is distinct from an oral tetracycline product, and systemic indications must not be transferred to it. The current catalogue specifies an ophthalmic presentation. This educational summary does not establish a Luang Pharma approved indication, a neonatal prophylaxis claim or the suitability of a particular finished formulation.
Clinical context and therapeutic role
Trachoma control is one public-health context in which antibiotic therapy is considered together with facial cleanliness, environmental measures and management of advanced disease. WHO guidance specifically discusses tetracycline eye ointment, but does not authorize this individual product. Other eye infections require their own diagnosis and current local guidance. Pain, light sensitivity, corneal symptoms or reduced vision warrant prompt professional assessment rather than treatment based solely on the presence of redness.
Selected safety context
Ophthalmic ointment may cause temporary blurred vision or local irritation. Previous tetracycline allergy and a reaction to any excipient need review. Avoid contaminating the tube tip or sharing the product. Persistent or worsening symptoms, severe swelling, eye pain or visual loss requires reassessment. Only a verified ophthalmic formulation should be used in the eye. Age eligibility, local contraindications and the in-use period must be established from current authorized product information.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This presentation is described as an ophthalmic ointment. It requires verified ophthalmic formulation and packaging; an ordinary skin ointment is not a substitute. The base, sterility requirements and container characteristics must be confirmed through the actual authorized product information and supporting product documentation.
Keep the tube tip clean and avoid contact with the eye or other surfaces. Do not share the tube. Temporary blur can affect activities requiring clear vision. Follow the actual label for storage and use after opening; no universal discard interval is assumed.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formula/specification identifying exact active form and ophthalmic base.
Sterility assurance, microbial controls and ophthalmic container-closure specification.
Approved label/leaflet with indication, age, application, after-opening and storage instructions.
Registration/market-status and manufacturing evidence for the exact ophthalmic presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| WHO: Trachoma Q&AArchived source classification: WHO public-health guidance | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| WHO medical product alert: tetracycline hydrochloride ophthalmic ointment 1%Archived source classification: WHO product-quality alert | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-043.
Professional enquiries
Request product-specific evidence for LP-043.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.